Compass Therapeutics (NASDAQ:CMPX) Releases Earnings Results, Beats Estimates By $0.01 EPS

Compass Therapeutics (NASDAQ:CMPX) released its quarterly earnings results on Thursday. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.01, FiscalAI reports.

Compass Therapeutics Stock Up 2.5%

CMPX traded up $0.14 during trading on Thursday, hitting $5.83. The company had a trading volume of 453,195 shares, compared to its average volume of 2,287,071. The company has a market capitalization of $1.04 billion, a PE ratio of -12.96 and a beta of 1.48. Compass Therapeutics has a one year low of $1.33 and a one year high of $6.88. The firm’s 50-day moving average price is $5.88 and its 200 day moving average price is $4.77.

Institutional Trading of Compass Therapeutics

A number of institutional investors have recently modified their holdings of the company. Russell Investments Group Ltd. raised its position in Compass Therapeutics by 3,933.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company’s stock valued at $27,000 after buying an additional 7,592 shares during the last quarter. Xponance LLC bought a new stake in shares of Compass Therapeutics in the fourth quarter worth $55,000. CIBC Bancorp USA Inc. acquired a new position in Compass Therapeutics during the third quarter worth $37,000. Creative Planning bought a new position in Compass Therapeutics in the second quarter valued at $30,000. Finally, Victory Capital Management Inc. increased its stake in Compass Therapeutics by 20.6% in the 3rd quarter. Victory Capital Management Inc. now owns 12,652 shares of the company’s stock valued at $44,000 after buying an additional 2,164 shares during the last quarter. 68.43% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Compass Therapeutics in a research note on Wednesday, January 21st. William Blair started coverage on Compass Therapeutics in a report on Monday, January 5th. They issued an “outperform” rating for the company. Canaccord Genuity Group set a $13.00 target price on Compass Therapeutics in a research note on Wednesday, February 4th. Craig Hallum started coverage on Compass Therapeutics in a research report on Friday, February 13th. They set a “buy” rating and a $15.00 target price for the company. Finally, Raymond James Financial reiterated an “outperform” rating and issued a $9.00 price target on shares of Compass Therapeutics in a research report on Tuesday, January 6th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Compass Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $13.36.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.